Jill Murphy is an associate editor for Pharmacy Times®. She graduated from Monmouth University in 2018 in communication and was previously a copywriter and communications specialist at a marketing agency prior to her start at the publication.
Phase 3 Trial Paused for CP101 in Recurrent C. difficle Infection
March 11th 2022Finch was still able to continue dosing patients in its past-ongoing PRISM-EXT phase 2 open-label trial of CP101 in recurrent CDI, because the CP101 lots used for PRISM-EXT were manufactured from material donated prior to December 1, 2019.
Read More
Experts Examine Ways to Reduce Global Burden of Depression
March 10th 2022The commission “Time for United Action on Depression,” authored by 25 experts from 11 countries, seeks to unify global efforts among governments, health care providers, researchers, people living with depression, and their families to improve care and prevention, fill knowledge gaps, and increase awareness.
Read More
AbbVie Seeks FDA Approval for Cariprazine for Adjunctive Treatment of Major Depressive Disorder
February 23rd 2022In a phase 3 study, there were clinically and statistically significant changes observed from baseline to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score for patients treated with cariprazine at 1.5 mg/day versus the placebo.
Read More
Study: Vaccinated Patients Less Likely to Need Critical Care During Omicron Surge
February 21st 2022During the period in which Omicron was the dominant variant, the researchers found that fewer patients died while hospitalized compared with those admitted when the Delta variant was dominant.
Read More